Phase II Trial of Emricasan in NASH Cirrhosis and Severe Portal Hypertension

April 10-14, 2019; Vienna, Austria
Although this trial did not meet the primary endpoint of decreasing mean hepatic venous pressure gradient in patients with NASH cirrhosis and severe portal hypertension, positive signals were seen that support additional exploration of emricasan in patients with severe portal hypertension.
Format: Microsoft PowerPoint (.ppt)
File Size: 183 KB
Released: April 17, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Learn from an expert about emerging strategies for combination treatment for NASH with GLP-1 receptor agonists plus SGLT2 inhibitors, from Clinical Care Options (CCO)

Manal F. Abdelmalek, MD, MPH Released: February 2, 2023

Experts review therapeutic interventions for NAFLD/NASH, from Clinical Care Options (CCO)

Manal F. Abdelmalek, MD, MPH
Program Director
Rohit Loomba, MD, MHSc Brent Tetri, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: 1.5 AAPA Category 1 CME Credits Released: December 7, 2022 Expired: December 6, 2023

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

Expert commentary by Dr Mark S. Sulkowski on the importance of investigating elevated liver enzymes in patients with HIV, from Clinical Care Options (CCO)

Mark S. Sulkowski, MD Released: January 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings